BioPharmSignal logoBioPharmSignal

Biotech News

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Kiora Pharmaceuticals (KPRX)Kiora PharmaceuticalsClinical readout

KPRX (KPRX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is kprx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

KPRXKiora Pharmaceuticals2026-03-25 11:00 EST

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

OCSOculis2026-06-09 08:00 EST

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

BLTEBelite Bio2026-07-20 12:00 EST

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

OCULOcular Therapeutix2026-04-13 11:00 EST

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

OCGNOcugen2026-04-01 11:02 EST

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

TARSTarsus Pharmaceuticals2026-03-31 12:30 EST

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

OCGNOcugen2026-03-24 11:45 EST

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

EYPTEyePoint Pharmaceuticals2026-07-30 11:00 EST

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

OKYOOKYO Pharma2026-07-20 11:00 EST

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

PRQRProQR Therapeutics2026-06-25 10:25 EST

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

View all latest news

Kiora Pharmaceuticals

Retinal-Disease Pipeline Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases. Its programs are designed to improve vision or preserve retinal function through mechanisms distinct from conventional gene-specific approaches. KIO-301 KIO-301 is a light-sensitive small molecule intended to restore visual signaling in...

Recent company news

KPRXKiora Pharmaceuticals2026-08-07 11:00 EST

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KPRXKiora Pharmaceuticals2026-07-02 11:00 EST

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

KPRXKiora Pharmaceuticals2026-06-18 11:00 EST

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

KPRXKiora Pharmaceuticals2026-05-08 11:00 EST

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

KPRXKiora Pharmaceuticals2026-04-14 11:00 EST

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Stock data

Close
2.56 USD
Market cap
12.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States